Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.53 |
| ▸ | HTR1D | P28221 | 15/20 | 0.57 |
| ▸ | HTR1B | P28222 | 13/20 | 0.57 |
| ▸ | HTR2A | P28223 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | FPR1 | P21462 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL30227183 | 1.00 | HTR1D (0.57) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL7175126 | 0.98 | HTR1D (0.59) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8148935 | 0.94 | HTR1D (0.65) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8154130 | 0.90 | HTR1D (0.59) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8147188 | 0.81 | HTR1D (0.66) | HTR1DHTR1BHTR2AMEN1MAPT | |
| Oxalic Acid SCHEMBL6924129 | 0.78 | HTR1D (0.86) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8816217 | 0.78 | HTR1D (0.62) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL5432776 | 0.78 | HTR1D (0.91) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8389415 | 0.76 | HTR1D (0.72) | HTR1DHTR1BHTR2AMEN1MAPT | |
| SCHEMBL8154054 | 0.76 | HTR1D (0.68) | HTR1DHTR1BHTR2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | claimed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |